Valor202020212022202320242025TTMGastos comerciales, generales y administrativos1.35 B1.82 B2.12 B2.63 B2.95 B2.7 B2.7 BInvestigación y desarrollo2.73 B2.91 B3.59 B4.44 B5.13 B5.85 B5.85 BBeneficio operativo3.58 B8.95 B4.74 B4.05 B3.99 B3.58 B3.58 BTotal de ingresos no operativos233.8 M379 M119.9 M152.2 M789.2 M1.65 B1.65 BGastos por intereses, netos de intereses capitalizados56.9 M57.3 M59.4 M73 M55.2 M43.8 M43.8 MIngresos no operativos, una vez deducidos los gastos por intereses-113.8 M-114.6 M-118.8 M-146 M-110.4 M-87.6 M-87.6 MIngresos/gastos extraordinarios290.7 M436.3 M179.3 M225.2 M844.4 M1.7 B1.7 BBeneficio antes de impuestos3.81 B9.33 B4.86 B4.2 B4.78 B5.23 B5.23 BParticipación en los beneficios———————Impuestos297.2 M1.25 B520.4 M245.7 M367.3 M725.8 M725.8 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos135 M-568.7 M-368 M100 K-23.5 M-135.5 M-135.5 MBeneficio neto antes de actividades interrumpidas3.51 B8.08 B4.34 B3.95 B4.41 B4.5 B4.5 BOperaciones suspendidas———————Beneficio neto3.51 B8.08 B4.34 B3.95 B4.41 B4.5 B4.5 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas3.51 B8.08 B4.34 B3.95 B4.41 B4.5 B4.5 BBeneficio básico por acción32.6576.440.5137.0540.943.0743.07Beneficio por acción diluido30.5271.9738.2234.7738.3441.4841.48Número medio de acciones ordinarias107.6 M105.7 M107.1 M106.7 M107.9 M104.6 M420 MAcciones diluidas115.1 M112.2 M113.5 M113.7 M115.1 M108.6 M435.6 MEBITDA3.81 B9.23 B5.08 B4.47 B4.47 B4.12 B4.12 BEBIT3.58 B8.95 B4.74 B4.05 B3.99 B3.58 B3.58 BCosto de los ingresos39.2 M457.1 M258.7 M102.3 M126.3 M172.9 M—Otros costes de producción39.2 M457.1 M258.7 M102.3 M126.3 M172.9 M—Amortización y depreciación (flujo de caja)235.9 M286.2 M341.4 M421 M482.9 M543.7 M543.7 M
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.